 |
|
|
| |
ACH-3102, A Second Generation NS5A Inhibitor, Demonstrates Potent Antiviral Activity in Patients with Genotype 1A HCV Infection Despite the Presence of Baseline NS5A-Resistant Variants
|
| |
| |
Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
A. Muir1, J. Hill2, E. Lawitz3, T. Marbury4, L. Robarge5, H. Robison5, J. Hui5, M. Huang5, A. Agarwal5, A. Perelson6, M. Deshpande5, H. Kocinsky5
1Duke Clinical Research Institute, Durham, NC; 2Avail Clinical Research, LLC, DeLand, FL; 3Alamo Medical Research, San Antonio, TX; 4Orlando, FL; 5Achillion Pharmaceuticals, Inc., New Haven, CT, 6Los Alamos National Laboratory, Los Alamos, NM
EASL/2012: PRECLINICAL CHARACTERISTICS OF ACH-3102: A NOVEL HCV NS5A INHIBITOR WITH IMPROVED POTENCY AGAINST GENOTYPE-1A VIRUS AND VARIANTS RESISTANT TO 1ST GENERATION NS5A INHIBITORS
http://www.natap.org/2012/EASL/EASL_79.htm
|
| |
|
|
|
|
|
